Our top pick for
Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
TRACON Pharmaceuticals, Inc is a biotechnology business based in the US. TRACON Pharmaceuticals shares (TCON) are listed on the NASDAQ and all prices are listed in US Dollars. TRACON Pharmaceuticals employs 19 staff and has a market cap (total outstanding shares value) of USD$121.7 million.
|52-week range||USD$0.95 - USD$10.108|
|50-day moving average||USD$5.9747|
|200-day moving average||USD$3.4202|
|Wall St. target price||USD$7.5|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-1.016|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|Gross profit TTM||USD$-14,530,000|
|Return on assets TTM||-40.23%|
|Return on equity TTM||-168.02%|
|Market capitalisation||USD$121.7 million|
TTM: trailing 12 months
There are currently 214,987 TRACON Pharmaceuticals shares held short by investors – that's known as TRACON Pharmaceuticals's "short interest". This figure is 7.5% down from 232,299 last month.
There are a few different ways that this level of interest in shorting TRACON Pharmaceuticals shares can be evaluated.
TRACON Pharmaceuticals's "short interest ratio" (SIR) is the quantity of TRACON Pharmaceuticals shares currently shorted divided by the average quantity of TRACON Pharmaceuticals shares traded daily (recently around 826873.07692308). TRACON Pharmaceuticals's SIR currently stands at 0.26. In other words for every 100,000 TRACON Pharmaceuticals shares traded daily on the market, roughly 260 shares are currently held short.
However TRACON Pharmaceuticals's short interest can also be evaluated against the total number of TRACON Pharmaceuticals shares, or, against the total number of tradable TRACON Pharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case TRACON Pharmaceuticals's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 TRACON Pharmaceuticals shares in existence, roughly 20 shares are currently held short) or 0.0167% of the tradable shares (for every 100,000 tradable TRACON Pharmaceuticals shares, roughly 17 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against TRACON Pharmaceuticals.
Find out more about how you can short TRACON Pharmaceuticals stock.
We're not expecting TRACON Pharmaceuticals to pay a dividend over the next 12 months.
TRACON Pharmaceuticals's shares were split on a 1:10 basis on 8 November 2019. So if you had owned 10 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your TRACON Pharmaceuticals shares – just the quantity. However, indirectly, the new 900% higher share price could have impacted the market appetite for TRACON Pharmaceuticals shares which in turn could have impacted TRACON Pharmaceuticals's share price.
Over the last 12 months, TRACON Pharmaceuticals's shares have ranged in value from as little as $0.95 up to $10.108. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while TRACON Pharmaceuticals's is 1.1359. This would suggest that TRACON Pharmaceuticals's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
TRACON Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for cancer and wet age-related macular degeneration (AMD). Its lead clinical stage products include envafolimab (KN035), an investigational PD-L1 single-domain antibody for the treatment of soft tissue sarcoma. The company's clinical stage products also include DE-122, which is in randomized Phase IIa study for the treatment of wet AMD; TRC102, which is a small molecule that is in Phase II clinical trial for the treatment of mesothelioma, Phase I clinical trial to treat solid tumors, Phase I/II to treat solid tumors and lymphomas, and Phase I trial to treat lung cancer; TRC253, a small molecule, which is in a Phase II clinical trial for the treatment of metastatic castration-resistant prostate cancer; and TJ004309, a CD73 antibody that is in Phase I clinical development for the treatment of solid tumors. It has collaboration and license agreements with 3D Medicines Co., Ltd. and Jiangsu Alphamab Biopharmaceuticals Co., Ltd. for the development of envafolimab; I-Mab Biopharma for the development of CD73 antibody TJ004309; Janssen Pharmaceutica N.V. for the development of TRC253; Santen Pharmaceutical Co. Ltd. for the development of carotuximab products for ophthalmology indications; Roswell Park Cancer Institute and Health Research Inc.; Case Western Reserve University; and cooperative research and development agreement with National Cancer Institute. The company was formerly known as Lexington Pharmaceuticals, Inc. and changed its name to TRACON Pharmaceuticals, Inc. in March 2005. TRACON Pharmaceuticals, Inc. was founded in 2004 and is headquartered in San Diego, California.
Steps to owning and managing CCF, with 24-hour and historical pricing before you buy.
Steps to owning and managing CDW, with 24-hour and historical pricing before you buy.
Steps to owning and managing CWH, with 24-hour and historical pricing before you buy.
Steps to owning and managing CBIO, with 24-hour and historical pricing before you buy.
Steps to owning and managing BLIN, with 24-hour and historical pricing before you buy.
Steps to owning and managing CVGW, with 24-hour and historical pricing before you buy.
Steps to owning and managing AEGN, with 24-hour and historical pricing before you buy.
Steps to owning and managing AJG, with 24-hour and historical pricing before you buy.
Steps to owning and managing ABB, with 24-hour and historical pricing before you buy.
Steps to owning and managing YGYI, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.